Source| Instrument FamilyRecently, the signing and unveiling ceremony of Medtronic's Digital Healthcare Innovation Base was held at the International Pharmaceutical Innovation Park (BioPark) located in Beijing's Yizhuang New Town.
According to reports,This base is the first digital healthcare innovation base established by Medtronic in China.
New Phase of Development in ChinaAccording to reports, the Medtronic Digital Healthcare Innovation Base is dedicated to developing disease management solutions based on artificial intelligence and big data.Will FocusCardiovascular, Minimally Invasive Surgery, NeuroscienceBuilding medical training centers in fields such as...; establishing patient care centers, introducing digital technology to enhance the service level of patient prevention and management; and simultaneously constructing the Medtronic Museum.The innovative base will be officially put into operation by the end of this year.The base is located in the International Medical Innovation Park (BioPark) in the western part of Yizhuang New City, Beijing. It is adjacent to the southern central axis on the west, with the southern Fifth Ring Road and JingTai Expressway as well as Subway Line 8 running through the area. Covering an area of 5.8 square kilometers, it is an important industrial functional zone in the comprehensive supporting service area of Yizhuang New City and even the southern part of the capital.This location is not only home to all six major centers of the National Medical Products Administration, but also attracts several multinational companies, including Medtronic.Including Eli Lilly, Pfizer, Bayer, HUYA Bioscience, and AstraZeneca.Most of these enterprises' newly established R&D or innovation institutions are "the first in Beijing" or "the first in China."
For example, Bayer will establish a new Open Innovation Center; Eli Lilly will set up a China Medical Innovation Center in Yizhuang, Beijing; Pfizer will establish its first physical R&D center in Beijing; HUYABIO will set up its China headquarters, becoming the first international platform in Beijing focusing on innovative drug exports. According to the plan, this year, the investment in the International Pharmaceutical Innovation Park will reach 10 billion yuan.
BioPark will be planned and built as a global hub for pharmaceuticals and health innovation cooperation, an international influential biopharmaceutical industry innovation cluster, the first stop for global pharmaceutical innovation talents to start businesses in China, a demonstration zone for AI-empowered applications in China's pharmaceuticals and health industry, and a "test field" for the implementation of national innovative pharmaceutical policies.
"After 36 years of deep cultivation in China, Medtronic has always been driven by innovation, resonating with the development of China's healthcare industry. The establishment of the Digital Healthcare Innovation Hub in Beijing marks a new phase in our full value chain presence in China. Leveraging Beijing’s leading medical resources and innovative momentum, we aim to collaborate with partners to create a patient-first digital healthcare innovation model."Reduce hospital burden, improve service efficiency, and enhance patient chronic disease management experience with solutions such as remote management and intelligent follow-up.", to help China build a smart and inclusive healthcare system." said Jeff Marrazzo, Global Chairman and CEO of Medtronic.
02
Recent Footprints of Medtronic Executives in ChinaNotably, the senior leadership of Medtronic has recently participated in several significant events and meetings with Chinese leaders.On March 23, He Lifeng, member of the Political Bureau of the CPC Central Committee and Vice Premier of the State Council, met with the heads of well-known multinational companies such as Medtronic, Apple, Pfizer, and Eli Lilly to exchange views on the global and Chinese economic situation, China-US economic and trade cooperation, and expanding investment in China.He Lifeng stated that China's economy is resilient, with great potential and vitality. China is firmly committed to promoting high-quality development, expanding high-level opening-up, continuously optimizing the business environment, and welcomes multinational companies to increase their investment in China to share development opportunities.Head of multinational corporation expresses重视中国市场, optimistic about China's economic前景, and willingness to commit to long-term cooperation with China.From March 23 to 24, the 2025 Annual Meeting of the China Development Forum was held in Beijing with the theme "Fully Unleashing Development Momentum, Jointly Promoting Stable Global Economic Growth," attracting political leaders from multiple countries and numerous heads of multinational corporations to attend the meeting in China.Medtronic Chairman and CEO Jeff Martha said during the annual meeting that Medtronic firmly believes China will become the world's largest healthcare market and an important source of innovation, as well as a strategic hub for medical innovation, investment, and collaboration. Medtronic looks forward to partnering with more industry collaborators to jointly promote the development of new productive forces, advance medical innovation, and improve patient outcomes.Jeff Massa said, "In 2025, Medtronic will enter its 36th year of development in China. Considering China's demographic structure, the growing healthcare needs, and the broader trend of China's economic development, the potential of China's healthcare market is undoubtedly enormous."On March 25, Cao Lijun, Member of the Standing Committee of the Sichuan Provincial Party Committee and Secretary of the Chengdu Municipal Party Committee, met with Jeff Martha, Global Chairman and CEO of Medtronic, and his entourage.Cao Lijun welcomed Jeff Masa and his team to Chengdu for inspection, exchange, and promotion of cooperation. He briefly introduced the economic and social development situation in Chengdu. He said that Chengdu is a hub city for exchanges between China and foreign countries and one of the most dynamic and happiest cities in China. At present, it is comprehensively building a demonstration zone for a park city that practices new development concepts, aiming to create a socialist modern international metropolis with global influence and reputation.As a global leading medical technology enterprise, Medtronic has maintained a good cooperative relationship with Chengdu for a long time. We hope the company will continue to increase its investment in Chengdu, bring more high-quality products, technologies, and services to China and specifically to Chengdu, strengthen exchanges and cooperation with Chengdu, and achieve win-win development. We will adhere to the principle of "responding to all needs without unnecessary interference," regularly carry out the initiative of "reaching out to tens of thousands of enterprises, solving problems, optimizing the environment, and promoting development," continuously create a first-class business environment that is market-oriented, law-based, and internationalized, and fully provide excellent conditions and high-quality services for enterprise development.Jeff Massa said that Chengdu has advantages in industry, talent, technology, and market, with a vibrant economic development, and he has high hopes for Chengdu's future.Will increase investment and cooperation in Chengdu, expand the layout of the industrial chain and value chain, actively integrate into the local innovation ecosystem, promote the落地应用 of new products and technologies in Chengdu, assist in the high-quality development of Chengdu's pharmaceuticals and health industry, and make greater contributions to enhancing the health and well-being of citizens.
03Continuously Increase Investment in ChinaRecentlyMedtronic in recent yearsMedtronic continues to increase its investment in China, building a localized full value chain layout. The key focus of the layout:The Lingang Medical Technology Industry Base is a cardiac disease management base that integrates high-end medical technology research and development with localized production, dedicated to providing China-market-focused cardiac disease solutions. Last year, the first product from this base was successfully launched.Kanghui Changzhou Science and Technology Park is a comprehensive innovation park in the orthopedics and neurosurgery fields, integrating production, research and development, incubation, and customer experience. The completion of this science park will have a profound impact on the medical technology industry in the Yangtze River Delta region. Currently, the building has been topped off, and the new science park building is expected to be operational by 2026.
Changzhou Kangdi Production Base: The Medtronic Kangdi Integrated Surgical Base project plans to introduce the most cutting-edge products and technologies in the global surgical field, creating a "smart" manufacturing base and innovation center that combines the production of high-end surgical products and equipment with innovative R&D incubation. This is an important layout by Medtronic in the surgical field. The project was officially signed on October 18 last year.
The Beijing Yizhuang Digital Innovation Service Base, which hosted this signing and unveiling event, represents an important endeavor by Medtronic in the field of digital healthcare. It is evident that Medtronic's presence in China is expanding across various fields and regions.
On February 18, 2025, Medtronic announced its financial results for the third quarter (Q3) of fiscal year 2025.The report shows that the company's revenue reached approximately US$8.3 billion (approximately RMB 61.093 billion), increasing by 2.5% on a reported basis and 4.1% on an organic basis.Achieved mid-single-digit organic revenue growth for the ninth consecutive quarter.
Editor: Qin Jiu (nrzx0321）
